LSE:GSKPharmaceuticals
Is GSK (LSE:GSK) Undervalued Following Jideytro Approval?
The latest move in GSK (LSE:GSK) stock interest is tied to the early US FDA approval of Jideytro for ROS1 positive non small cell lung cancer, which expands the company’s oncology footprint.
See our latest analysis for GSK.
Despite the Jideytro approval and a series of recent product updates in vaccines and oncology, GSK’s share price has drifted lower over the past quarter. However, its 1 year total shareholder return of 42.21% and 5 year total shareholder return of 65.00% still point to...